2026 Q1 Portfolio Activity
In 2026 Q1, Samsara BioCapital, LLC maintained a portfolio of 24 distinct positions. The most significant new addition was SPYGLASS PHARMA INC, now representing 5.31% of the total fund value. They heavily accumulated shares in ALUMIS INC, increasing the position by 10.2%. The fund also reduced its exposure to PALVELLA THERAPEUTICS INC NE by 63.3%.
Position History
hover any row below to update
Loading…
Total Positions
24
Quarter
2026 Q1
Top Holding
SRRK (32.9%)
Top 10 Concentration
92.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-24 of 24
Samsara BioCapital, LLC Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
SRRK
SCHOLAR ROCK HL...
|
Healthcare | 32.95% | 31.35% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
6,897,652 | $339,088,572 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MLYS
MINERALYS THERA...
|
Healthcare | 15.45% | 21.98% |
#2
Prev: #2
|
6.5 |
—
|
no change | no change |
P
S
|
5,871,018 | $159,045,878 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALMS
ALUMIS INC
|
Healthcare | 13.58% | 5.80% |
#3
2
Prev: #5
|
7.0 |
—
|
588,235 | 10.2% |
P
S
|
6,345,219 | $139,785,175 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SEPN
SEPTERNA INC
|
Healthcare | 7.35% | 9.06% |
#4
Prev: #4
|
4.4 |
—
|
no change | no change |
P
S
|
3,149,128 | $75,673,546 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KLRS
KALARIS THERAPE...
|
Healthcare | 7.26% | 11.27% |
#5
2
Prev: #3
|
4.4 |
—
|
no change | no change |
P
S
|
12,948,081 | $74,710,427 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
SPYGLASS PHARMA...
|
|
Unknown | 5.31% | — |
#6
Prev: #—
|
5.6 |
—
|
2,109,953 | — |
NEW
|
2,109,953 | $54,668,882 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
NGNE
NEUROGENE INC
|
Healthcare | 3.36% | 3.65% |
#7
1
Prev: #6
|
2.3 |
—
|
no change | no change |
P
S
|
1,717,127 | $34,617,280 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IVA
INVENTIVA SA
|
Healthcare | 2.80% | 2.49% |
#8
1
Prev: #7
|
2.1 |
—
|
no change | no change |
P
S
|
5,194,805 | $28,831,168 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
STRO
SUTRO BIOPHARMA...
|
Healthcare | 2.57% | 0.24% |
#9
10
Prev: #19
|
4.0 |
—
|
858,369 | 419.7% |
P
S
|
1,062,872 | $26,476,142 | 2018 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
JBIO
JADE BIOSCIENCE...
|
Healthcare | 1.32% | 1.54% |
#10
1
Prev: #11
|
1.5 |
—
|
no change | no change |
P
S
|
968,798 | $13,611,612 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VTVT
VTV THERAPEUTIC...
|
Healthcare | 1.15% | 1.23% |
#11
1
Prev: #12
|
1.5 |
—
|
no change | no change |
P
S
|
298,496 | $11,838,351 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AQST
AQUESTIVE THERA...
|
Healthcare | 1.01% | 1.67% |
#12
2
Prev: #10
|
1.4 |
—
|
no change | no change |
P
S
|
2,500,000 | $10,375,000 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 0.74% | 0.81% |
#13
3
Prev: #16
|
0.8 |
—
|
-127,434 | -6.5% |
P
S
|
1,832,566 | $7,568,498 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NKTX
NKARTA INC
|
Healthcare | 0.72% | 0.67% |
#14
3
Prev: #17
|
1.3 |
—
|
no change | no change |
P
S
|
3,507,666 | $7,401,175 | 2020 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ACLX
ARCELLX INC
|
Healthcare | 0.68% | 0.41% |
#15
3
Prev: #18
|
1.3 |
—
|
no change | no change |
P
S
|
60,873 | $6,989,438 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
UPB
UPSTREAM BIO IN...
|
Healthcare | 0.64% | 2.06% |
#16
7
Prev: #9
|
1.3 |
—
|
no change | no change |
P
S
|
736,047 | $6,624,423 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 0.61% | 1.05% |
#17
2
Prev: #15
|
0.2 |
—
|
-18,861 | -25.0% |
P
S
|
56,581 | $6,300,294 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
AGOMAB THERAPEU...
|
|
Unknown | 0.61% | — |
#18
Prev: #—
|
3.7 |
—
|
600,000 | — |
NEW
|
600,000 | $6,294,000 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
RANI
RANI THERAPEUTI...
|
Healthcare | 0.61% | 1.18% |
#19
6
Prev: #13
|
1.2 |
—
|
no change | no change |
P
S
|
8,500,000 | $6,245,800 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CHRS
COHERUS ONCOLOG...
|
Healthcare | 0.56% | — |
#20
Prev: #—
|
3.7 |
—
|
3,428,571 | — |
NEW
|
3,428,571 | $5,794,285 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PVLA
PALVELLA THERAP...
|
Healthcare | 0.47% | 1.13% |
#21
7
Prev: #14
|
0.2 |
—
|
-66,385 | -63.3% |
P
S
|
38,432 | $4,790,549 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GOSS
GOSSAMER BIO IN...
|
Healthcare | 0.23% | 2.31% |
#22
14
Prev: #8
|
1.1 |
—
|
no change | no change |
P
S
|
7,222,559 | $2,372,611 | 2019 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NUVB/WS
NUVATION BIO IN...
|
Unknown | 0.00% | 0.00% |
Sold All 😨
(Was: #21) |
0.0 |
—
|
-124,119 | -100.0% |
CLOSED
|
— | $— | 2022 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CTNM
CONTINEUM THERA...
|
Healthcare | 0.00% | 0.09% |
Sold All 😨
(Was: #20) |
0.0 |
—
|
-72,245 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-24 of 24 holdings